You are here: Industry Insights > CD38

News List

I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China prnasia
October 14, 2021
I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it has completed the patient...
Researchers find CD38-targeting drugs may show promise against prostate cancer pharmatimes
May 11, 2021
A new study suggests that drugs which target the CD38 protein molecule may show promise against prostate cancer by ‘reawakening’ the body’s immune response against this tumour type.
CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program prnewswire
June 09, 2020
CASI Pharmaceuticals, Inc. announced that it submitted a Clinical Trial Application (CTA) (IND) with the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for CID-103.
Genmab, Janssen Partner for Next-Gen CD38 Antibody contractpharma
June 20, 2019
To collaborate on HexaBody-CD38, a next-generation CD38 antibody product incorporating Genmab's HexaBody technology.